Clinical Trial Update: A Study of JNJ-55308942 in the Treatment of Bipolar Depression [Phase 2]

View source ↗

Summary

A Phase 2 study of JNJ-55308942 for bipolar depression has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• JNJ-55308942

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Bipolar Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-07-11